Abemaciclib Shows Activity for HR-Positive Breast Cancer Brain Mets

Video

This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.

Current Time 
Duration 
Loaded: 0%
Stream Type LIVE
Remaining Time 
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected

      In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses an early trial studying the CDK4/6 inhibitor abemaciclib for the treatment of brain metastases in patients with hormone receptor (HR)-positive HER2-negative breast cancer.

      Tolaney presented the study results (abstract 1019) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

      Recent Videos
      Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
      Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
      CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
      CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
      5 experts in this video
      TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
      5 experts in this video
      Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
      Adjuvant Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      Adjuvant Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
      The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
      Patient Selection and Timing Considerations for CAR T Therapy
      Patient Selection and Timing Considerations for CAR T Therapy
      Long-Term Efficacy and Real-World Outcomes With Liso-cel
      Long-Term Efficacy and Real-World Outcomes With Liso-cel
      Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
      Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
      Related Content
      Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

      Active Monitoring May Be Safe Vs Surgery in Certain Low-Risk DCIS Populations

      Russ Conroy
      March 10th 2025
      Article

      Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

      Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

      Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

      Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
      March 10th 2025
      Podcast

      Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

      3 Things You Should Know About Treating Epithelioid Sarcoma

      3 Things You Should Know About Treating Epithelioid Sarcoma

      ONCOLOGY Staff
      March 10th 2025
      Article

      Epithelioid sarcoma is individualized based on disease characteristics, it's methods of treatment vary, and systemic treatment is both targeted medication and chemotherapy.

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
      March 7th 2025
      Podcast

      A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

      Pooled analysis data support atezolizumab continuation as a viable second-line therapy option in extensive-stage small cell lung cancer.

      Continued Atezolizumab Shows Durable Benefit in Pretreated ES-SCLC

      Russ Conroy
      March 9th 2025
      Article

      Pooled analysis data support atezolizumab continuation as a viable second-line therapy option in extensive-stage small cell lung cancer.

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      ONCOLOGY Staff
      March 9th 2025
      Article

      A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.